Share Name Share Symbol Market Type
Merck and Co Inc NYSE:MRK NYSE Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  -0.16 -0.2% 78.25 79.18 78.16 79.04 10,437,137 23:34:13

Alkermes in Trial, Supply Agreement With Merck for Ovarian Cancer Treatment

07/04/2021 1:01pm

Dow Jones News

Merck (NYSE:MRK)
Historical Stock Chart

From Mar 2021 to May 2021

Click Here for more Merck Charts.

By Chris Wack


Alkermes PLC said Wednesday it has entered into a clinical trial collaboration and supply agreement with Merck & Co. to evaluate nemvaleukin alfa in combination with Keytruda in comparison with investigator choice chemotherapy in patients with platinum-resistant ovarian cancer.

Under the terms of the agreement, Alkermes is responsible for conducting the Phase 3 study, which is planned to begin in the second half of 2021.

Nemvaleukin is Alkermes's novel investigational engineered interleukin-2 variant for immunotherapy.

Alkermes said nemvaleukin in combination with Keytruda has demonstrated antitumor activity in heavily pre-treated patients with platinum-resistant ovarian cancer in an ongoing study, with durable and deepening responses observed.

Alkermes shares were up 5% to $20.10 in premarket trading.


Write to Chris Wack at


(END) Dow Jones Newswires

April 07, 2021 07:46 ET (11:46 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

1 Year Merck Chart

1 Year Merck Chart

1 Month Merck Chart

1 Month Merck Chart
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210510 22:51:49